David A. Siegel Lexicon Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.06 - $2.33 $36,934 - $81,186	34,844 New	34,844 $37,000
Q3 2021 Nov 15, 2021	SELL	$3.38 - $5.35 $1.21 Million - $1.92 Million	-359,316 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$4.12 - $5.87 $1.21 Million - $1.73 Million	294,743 Added 456.45%	359,316 $1.65 Million
Q1 2021 May 17, 2021	BUY	$3.45 - $9.09 $222,776 - $586,968	64,573 New	64,573 $379,000
Q3 2020 Nov 16, 2020	SELL	$1.44 - $2.1 $656,375 - $957,213	-455,816 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.75 - $2.3 $31,325 - $41,170	17,900 Added 4.09%	455,816 $909,000
Q1 2020 May 15, 2020	BUY	$1.8 - $4.28 $266,760 - $634,296	148,200 Added 51.15%	437,916 $854,000
Q4 2019 Feb 14, 2020	BUY	$3.16 - $5.15 $714,476 - $1.16 Million	226,100 Added 355.41%	289,716 $1.2 Million
Q3 2019 Nov 14, 2019	BUY	$1.2 - $6.66 $43,920 - $243,756	36,600 Added 135.48%	63,616 $191,000
Q2 2019 Aug 14, 2019	SELL	$5.35 - $7.11 $52,965 - $70,389	-9,900 Reduced 26.82%	27,016 $170,000
Q1 2019 May 15, 2019	BUY	$4.36 - $7.94 $37,060 - $67,490	8,500 Added 29.91%	36,916 $205,000
Q4 2018 Feb 14, 2019	BUY	$6.15 - $10.51 $78,344 - $133,886	12,739 Added 81.26%	28,416 $189,000
Q3 2018 Nov 14, 2018	SELL	$10.32 - $13.06 $187,824 - $237,692	-18,200 Reduced 53.72%	15,677 $167,000
Q2 2018 Aug 14, 2018	BUY	$7.8 - $13.69 $149,986 - $263,245	19,229 Added 131.27%	33,877 $407,000
Q1 2018 May 15, 2018	BUY	$7.86 - $11.39 $32,005 - $46,380	4,072 Added 38.5%	14,648 $126,000
Q4 2017 Feb 14, 2018	BUY	$8.77 - $12.28 $92,751 - $129,873	10,576	10,576 $104,000

141

238M

459K

133K

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $185M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.